Gelion plc

("Gelion" or the "Company")

Block Admission Return

The Company provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:

а	Name of company	Gelion plc	
b	Name of scheme	Gelion plc scheme: Existing Share Option Plan	<u>Shares</u>
		8,100,000	
с	Period of return (from/ to)	26 July 2024 to 26 January 2025	
d	Number and Class of Securities not issued at the start of the period under the scheme	7,901,856 ordinary shares of 0.1p each	
е	Additional listing	Nil	
f	Number of securities issued under the scheme during the period	Existing Share Option Plan	<u>Shares</u> Nil
g	Balance under the scheme of securities not yet issued at the end of the period	Existing Share Option Plan 7,901,856	<u>Shares</u>
h	Number and class of securities originally admitted and the date of admission	8,100,000 ordinary shares of 0.1p each	
i	Contact name - Company Telephone number	Amit Gupta +44 20 3405 0205	
	Contact name - Cavendish Capital Markets Limited Telephone number	Neil McDonald +44 020 7220 0500	

CONTACTS

Gelion plc John Wood, CEO Amit Gupta, CFO	via Alma
Cavendish Capital Markets Limited (Nominated Adviser and Broker) Neil McDonald (Corporate Finance)	+44 207 220 0500
Seamus Fricker (Corporate Finance)	
Adam Rae (Corporate Finance)	
Louise Talbot (Sales)	

Alma Strategic Communications (Financial PR Adviser) Justine James Hannah Campbell Will Ellis Hancock +44 20 3405 0205 gelion@almastrategic.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how

RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLRPKQBBABKDODB